<?xml version="1.0" encoding="UTF-8"?>
<p>Several pathways for the suspected antiviral effects found with azithromycin have been suggested. Firstly, as mentioned regarding CQ and HCQ, azithromycin is a weak base that could inhibit endocytosis, thus limiting viral entry and replication [
 <xref rid="B122-pharmaceuticals-13-00096" ref-type="bibr">122</xref>]. Secondly, azithromycin directly affects the activity of bronchial epithelial cells and decreases mucus production, thus improving lung function [
 <xref rid="B123-pharmaceuticals-13-00096" ref-type="bibr">123</xref>]. Thirdly, there is evidence suggesting that azithromycin increases the production of IFN via the stimulation of IFN genes, leading to a reduction of viral replication [
 <xref rid="B124-pharmaceuticals-13-00096" ref-type="bibr">124</xref>]. Lastly and recently, azithromycin was shown to directly intervene with the SARS-CoV-2 host cell entry by inhibiting the interaction between SARS-CoV-2 spike protein and the host cell receptor, ACE2 [
 <xref rid="B125-pharmaceuticals-13-00096" ref-type="bibr">125</xref>].
</p>
